Table 2.
relationship between expression of mir-1307-5p and clinicopathological factors
| Pathological parameters | n | Expression level of mir-1307-5p | ||
|---|---|---|---|---|
| high expression | Low expression | P | ||
| Age | ||||
| <55 | 28 | 18 (30.5%) | 10 (32.3%) | |
| 0.524 | ||||
| ≥ 55 | 62 | 41 (69.5%) | 21 (67.7%) | |
| Gender | ||||
| Male | 46 | 34 (57.6%) | 12 (38.7%) | |
| 0.069 | ||||
| Female | 44 | 25 (42.4%) | 19 (61.3%) | |
| Pathological stage | ||||
| I | 15 | 10 (16.9%) | 5 (16.1%) | |
| II | 55 | 36 (61.0%) | 19 (61.3%) | 0.994 |
| III | 20 | 13 (22.0%) | 7 (22.6%) | |
| TNM staging | ||||
| T | ||||
| T1 | 65 | 47 (79.7%) | 18 (58.1%) | |
| T2 | 21 | 11 (18.6%) | 10 (32.3%) | |
| 0.027 | ||||
| T3 | 3 | 0 (0.0%) | 3 (9.7%) | |
| T4 | 1 | 1 (1.7%) | 0 (0.0%) | |
| N | ||||
| N0 | 56 | 36 (61.0%) | 20 (64.5%) | |
| N1 | 21 | 15 (25.4%) | 6 (19.4%) | |
| 0.797 | ||||
| N2 | 13 | 8 (13.6%) | 5 (16.1%) | |
| N3 | 0 | 0 (0.0%) | 0 (0.0%) | |
| M | ||||
| M0 | 90 | 43 (72.9%) | 22 (71.0%) | |
| 0.517 | ||||
| M1 | 2 | 16 (27.1%) | 9 (29.0%) | |
| Clinical stages | ||||
| I | 40 | 25 (42.4%) | 15 (48.4%) | |
| II | 19 | 15 (25.4%) | 4 (12.9%) | |
| 0.504 | ||||
| III | 6 | 3 (5.1%) | 3 (9.7%) | |
| IV | 25 | 16 (27.1%) | 9 (29.0%) | |